IR@PKUHSC  > 北京大学第一临床医学院  > 临床药理研究所
学科主题药理学
美罗培南与泰能随机对照治疗细菌性感染临床评价
其他题名A randomized, controlled clinical trial on meropenem versus imipenem/ cilastatin for the treatment of bacterial infections
侯芳1; 李家泰1; 吴国平1; 郑波1; 陈亦芳1; 顾俊明1; 王慧玲1; 霍丽1; 薜欣1; 贾长绪1; 尹永红1; 田晓峰1; 任双义1
关键词美罗培南 泰能 感染 Meropenem Imipenem/cilastatin Infection
刊名中华医学杂志(英文版)
2002
DOI10.3760/j.issn:0366-6999.2002.12.019
115期:12页:1849-1854
文章类型Journal Article
摘要目的评价美罗培南的安全性和有效性.方法共入选182例,其中试验组90例,疗效评价70例,不良反应评价72例;对照组92例,疗效评价70例,不良反应评价70例.组药方法为美罗培南500 mg/次,Q12 h (必要时1 g,Q12 h),静脉点滴30分钟;泰能(亚胺培南/西司他丁,500 mg/500 mg),500 mg/次,Q 12 h(必要时1 g, Q12 h),静脉点滴30分钟,疗程均为7-14天.结果两药临床有效率分别为90%与87%,细菌清除率分别为86%(55/64)和86%(57/66),76%(93/123)的临床分离致病菌进行株致病菌产β-内酰胺酶阳性.不良反应发生率分别为9.7%(7/72)与8.6%(6/70).以上结果经统计学处理无显著差异(P>0.05).结论美罗培南治疗细菌性感染(包括酶菌感染)安全有效. Objective To evaluate the efficacy and safety of meropenem in Chinese patients, we conducted a study for the treatment of patients with lower respiratory tract infections, urinary tract infections and other infections. Methods A total of 182 hospitalized patients were enrolled in the study. 90 patients received 500 mg meropenem every 12 hours (or 1 g every 12 hours if necessary) and 92 patients received imipenem/cilastatin 500 mg/500 mg every 12 hours (or 1 g every 12 hours if necessary) by intravenous infusion. The duration of treatment was 7-14 days for both groups. Results Seventy of 90 cases receiving meropenem and 70 of 92 cases receiving imipenem/cilastatin were assessable for clinical efficacy. The overall efficacy rates were 90% for the meropenem group and 87% for the imipenem/cilastatin group, and the bacterial eradication rates were 86% in both groups. 93 (76%) of 123 strains isolated from patients produced β-lactamases. Adverse drug reactions were evaluated in 72 cases in the meropenem group and 70 cases in the imipenem/cilastatin group. The adverse drug reaction rates were 9.7% and 8.6%, respectively. The results showed that there were no statistical differences between these two groups (P>0.05). Conclusion Meropenem is effective and safe for the treatment of bacterial infections caused mainly by beta-lactamase-producing strains.
语种中文
原文出处查看原文
引用统计
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/44294
专题北京大学第一临床医学院_临床药理研究所
作者单位1.北京大学第一医院临床药理研究所,北京,100034
2.大连医科大学第二附属医院呼吸内科 大连 116023
推荐引用方式
GB/T 7714
侯芳,李家泰,吴国平,等. 美罗培南与泰能随机对照治疗细菌性感染临床评价[J]. 中华医学杂志(英文版),2002,115(12):1849-1854.
APA 侯芳.,李家泰.,吴国平.,郑波.,陈亦芳.,...&任双义.(2002).美罗培南与泰能随机对照治疗细菌性感染临床评价.中华医学杂志(英文版),115(12),1849-1854.
MLA 侯芳,et al."美罗培南与泰能随机对照治疗细菌性感染临床评价".中华医学杂志(英文版) 115.12(2002):1849-1854.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[侯芳]的文章
[李家泰]的文章
[吴国平]的文章
百度学术
百度学术中相似的文章
[侯芳]的文章
[李家泰]的文章
[吴国平]的文章
必应学术
必应学术中相似的文章
[侯芳]的文章
[李家泰]的文章
[吴国平]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。